Research programme: monoclonal antibody HUIV 26-derived cancer therapies - Micromet
Alternative Names: 2D4; H8Latest Information Update: 12 Mar 2008
At a glance
- Originator University of Southern California
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Choroidal neovascularisation; Solid tumours
Most Recent Events
- 05 May 2006 CancerVax Corporation merged with Micromet AG to form Micromet Inc
- 15 Nov 2005 Eyetech Pharmaceuticals has been acquired by OSI Pharmaceuticals
- 09 May 2005 Data presented at the 96th Annual Meeting of the American Association for Cancer Research (AACR-2005) have been added to the Cancer pharmacodynamics section